Synaptogenix Files 8-K: Director/Officer Changes & Financials
Ticker: TAOX · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1571934
| Field | Detail |
|---|---|
| Company | Synaptogenix, Inc. (TAOX) |
| Form Type | 8-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $12,500, $16,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, corporate-governance, financials
TL;DR
Synaptogenix 8-K: Leadership shakeup and financial updates filed.
AI Summary
Synaptogenix, Inc. filed an 8-K on December 20, 2024, reporting events as of December 16, 2024. The filing indicates changes related to directors and officers, including potential elections, appointments, and compensatory arrangements. It also covers other events and financial statement disclosures.
Why It Matters
This 8-K filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with financial disclosures, can indicate significant internal shifts that may affect the company's future performance and stability.
Key Players & Entities
- Synaptogenix, Inc. (company) — Registrant
- December 16, 2024 (date) — Earliest event reported date
- December 20, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 1185 Avenue of the Americas, 3rd Floor New York, New York 10036 (address) — Principal executive offices
FAQ
What specific changes occurred regarding directors or officers of Synaptogenix, Inc. as reported in this 8-K?
The 8-K filing indicates events related to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
When was the earliest event reported in this Synaptogenix 8-K filing?
The earliest event reported in this filing was on December 16, 2024.
What is the filing date of this 8-K for Synaptogenix, Inc.?
This 8-K filing was made on December 20, 2024.
What is the principal executive office address for Synaptogenix, Inc.?
The principal executive office address is 1185 Avenue of the Americas, 3rd Floor, New York, New York 10036.
What are the main items covered in this 8-K filing by Synaptogenix, Inc.?
This 8-K filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, other events, and financial statements and exhibits.
Filing Stats: 909 words · 4 min read · ~3 pages · Grade level 9.3 · Accepted 2024-12-20 09:21:09
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share SNPX The Nasdaq
- $12,500 — an's base monthly salary to the rate of $12,500 per month. This reduction in salary is
- $16,000 — . Alkon's consulting fee to the rate of $16,000 per month. This reduction in consulting
Filing Documents
- tm2431397d1_8k.htm (8-K) — 31KB
- tm2431397d1_ex10-1.htm (EX-10.1) — 8KB
- tm2431397d1_ex10-2.htm (EX-10.2) — 40KB
- tm2431397d1_ex99-1.htm (EX-99.1) — 8KB
- 0001104659-24-130537.txt ( ) — 276KB
- snpx-20241216.xsd (EX-101.SCH) — 3KB
- snpx-20241216_lab.xml (EX-101.LAB) — 33KB
- snpx-20241216_pre.xml (EX-101.PRE) — 22KB
- tm2431397d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. Press Release On December 20, 2024, the Company issued a press release announcing the formation of a special committee to explore strategic opportunities to create and enhance value for investors. A copy of the press release is attached as Exhibit 99.1 hereto. Termination of Agreement related to Bryostatin-1 clinical trial On December 20, 2024, the Company announced via press release that it engaged in various actions designed to reduce the Company's burn rate related to clinical trials for Bryostatin-1, the Company's novel drug candidate targeting the activation of Protein Kinase C Epsilon. Among the actions taken was the delivery of a termination notice pursuant to its agreement to conduct a Phase 1 trial of Bryostatin-1 in multiple sclerosis, due to the slow pace of enrollment in the clinical trial.
Financial Statements
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 10.1 Amendment to the offer letter, dated December 16, 2024, by and between the Company and Alan J. Tuchman, M.D. 10.2 Consulting Agreement, dated December 16, 2024, by and between the Company and Dr. Daniel L. Alkon, M.D. 99.1 Press release, dated December 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SYNAPTOGENIX, INC. Date: December 20, 2024 By: /s/ Robert Weinstein Name: Robert Weinstein Title: Chief Financial Officer